{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:37:16Z","timestamp":1791308236959,"version":"4.3.1"},"reference-count":37,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Isavuconazole is a newer broad-spectrum triazole approved for the treatment of invasive fungal disease. The objective of this study was to conduct a population pharmacokinetic and pharmacodynamic analysis of isavuconazole in a retrospective cohort of hospitalized patients. A nonlinear mixed-effect approach with Monte Carlo simulations was conducted to assess the probability of target attainment (PTA) of an area under the concentration\u2013time curve (AUC24 h)\/minimum inhibitory concentration (MIC) ratio of 33.4 (defined as efficacy threshold against A. fumigatus and A. flavus) associated with a maintenance dose (MD) of 100, 200 and 300 mg daily after loading. The cumulative fraction of response (CFR) against the EUCAST MIC distributions of A. fumigatus and A. flavus was calculated as well. The proportion of trough concentrations (Ctrough) exceeding a defined threshold of toxicity (&gt;5.13 mg\/L) was estimated. A total of 50 patients, with a median age of 61.5 years, provided 199 plasma isavuconazole concentrations. Invasive pulmonary aspergillosis was the prevalent type of infection and accounted for 80% (40\/50) of cases. No clinical covariates were retained by the model. With the standard MD of 200 mg daily, CFRs were always \u226590% during the first two months of treatment. The risk of Ctrough &lt; 1.0 mg\/L was around 1%, and that of Ctrough &gt; 5.13 mg\/L was 27.7 and 39.2% at 28 and 60 days, respectively, due to isavuconazole accumulation over time. Our findings suggest that TDM for isavuconazole should not be considered as mandatory as for the other mold-active azoles voriconazole and posaconazole.<\/jats:p>","DOI":"10.3390\/pharmaceutics13122099","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T02:48:13Z","timestamp":1638845293000},"page":"2099","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?"],"prefix":"10.3390","volume":"13","author":[{"given":"Pier Giorgio","family":"Cojutti","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy"},{"name":"SSD Clinical Pharmacology, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Carnelutti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Lazzarotto","sequence":"additional","affiliation":[{"name":"Division of Haematology, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Sozio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-1310","authenticated-orcid":false,"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[{"name":"Division of Haematology, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[{"name":"Division of Haematology, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy"},{"name":"Department of Medicine, University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Santa Maria della Misericordia University Hospital of Udine, ASUFC, 33100 Udine, Italy"},{"name":"Department of Medicine, University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-7167","authenticated-orcid":false,"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"name":"SSD Clinical Pharmacology, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.12628","article-title":"Improving outcome of fungal diseases\u2014Guiding experts and patients towards excellence","volume":"60","author":"Cornely","year":"2017","journal-title":"Mycoses"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","article-title":"The Changing Epidemiology of Invasive Fungal Infections","volume":"Volume 1508","author":"Enoch","year":"2017","journal-title":"Human Fungal Pathogen Identification"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/tid.12186","article-title":"Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"16","author":"Kauffman","year":"2014","journal-title":"Transpl. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","article-title":"Epidemiology of invasive aspergillosis in critically ill patients: Clinical presentation, underlying conditions, and outcomes","volume":"19","author":"Taccone","year":"2015","journal-title":"Crit. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s15010-013-0539-3","article-title":"SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients","volume":"42","author":"Montagna","year":"2014","journal-title":"Infection"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/phar.1652","article-title":"Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent","volume":"35","author":"Rybak","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1060028015581679","article-title":"Isavuconazole: A New Option for the Management of Invasive Fungal Infections","volume":"49","author":"Pettit","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s40265-016-0652-6","article-title":"Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: Pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e00585-18","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/1120009X.2017.1418619","article-title":"Hepatic veno-occlusive disease during isavuconazole administration","volume":"30","author":"Mesini","year":"2018","journal-title":"J. Chemother."},{"key":"ref_16","unstructured":"(2020, June 16). European Committee on Antimicrobial Susceptibility Testing. Isavuconazole and Aspergillus spp.: Rationale for the Clinical Breakpoints, Version 2.0, Available online: http:\/\/www.eucast.org."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/FTD.0000000000000632","article-title":"Interlaboratory Analysis of Isavuconazole Plasma Concentration Assays Among European Laboratories","volume":"41","author":"Pea","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2019). Electronic Address, e.e.e.; Clinical Practice Guideline Panel, C.; Panel, m.; Representative, E.G.B. EASL Clinical Practice Guidelines: Drug-Induced liver injury. J. Hepatol., 70, 1222\u20131261.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"ref_19","unstructured":"(2020, June 16). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, Available online: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.04907-14","article-title":"Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model","volume":"59","author":"Seyedmousavi","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","unstructured":"(2020, June 16). The European Committee on Antimicrobial Susceptibility Testing-EUCAST. Available online: https:\/\/www.eucast.org\/mic_distributions_and_ecoffs."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1128\/AAC.02942-15","article-title":"Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00101-17","DOI":"10.1128\/AAC.00101-17","article-title":"Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole","volume":"61","author":"Kovanda","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e01728-19","DOI":"10.1128\/AAC.01728-19","article-title":"Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/jac\/dkw098","article-title":"Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: Implications for clinical breakpoints","volume":"71","author":"Kovanda","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Risum, M., Vestergaard, M.B., Weinreich, U.M., Helleberg, M., Vissing, N.H., and Jorgensen, R. (2021). Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole. Antibiotics, 10.","DOI":"10.3390\/antibiotics10050487"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole with the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cpdd.282","article-title":"Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg\/Ritonavir 100 mg in Healthy Subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole with Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol\/Norethindrone in Healthy Adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Roos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/mmy\/myaa022","article-title":"Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center","volume":"58","author":"Borman","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e01511-20","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2099\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:42:04Z","timestamp":1760168524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["pharmaceutics13122099"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13122099","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]}}}